{"nctId":"NCT00614380","briefTitle":"Open Label Study Telmisartan and Amlodipine in Hypertension","startDateStruct":{"date":"2008-01"},"conditions":["Hypertension"],"count":976,"armGroups":[],"interventions":[{"name":"telmisartan/amlodipine 40/5 mg fixed combination","otherNames":[]},{"name":"telmisartan/amlodipine 80/5 mg fixed combination","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. patients aged at least 18 years\n2. diagnosis of essential hypertension and blood pressure not adequately controlled before enrolment in the preceding trial.\n3. failure to respond to six weeks treatment with Amlodipine 5 mg in the run-in period of the preceding trial.\n\nExclusion Criteria:\n\n1. pre-menopausal women who are not surgically sterile; or are nursing or pregnant; or are not practising acceptable means of birth control or do not plan to continue using acceptable means of birth control throughout the study\n2. development of any medical condition in the preceding trial that in the investigator's opinion could be worsened by treatment with either Telmisartan 40 mg/Amlodipine 5 mg or Telmisartan 80 mg/Amlodipine 5 mg\n3. discontinuation from the preceding trial because of any adverse event or any other reason\n4. known or suspected secondary hypertension\n5. mean seated Systolic Blood Pressure =\\> 180 mmHg and/or mean seated Diastolic Blood Pressure =\\> 120 mmHg at any visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough Seated Diastolic Blood Pressure (DBP) Control","description":"The number of patients who reach the target DBP of \\<90mmHg","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"504","spread":null},{"groupId":"OG001","value":"160","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"97","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Seated Systolic Blood Pressure (SBP) Control","description":"The number of patients who reach the target SBP of \\<140mmHg","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"440","spread":null},{"groupId":"OG001","value":"142","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"92","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough Seated Diastolic Blood Pressure","description":"Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.5.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.18","spread":"0.31"},{"groupId":"OG001","value":"-12.64","spread":"0.52"},{"groupId":"OG002","value":"-9.47","spread":"1.51"},{"groupId":"OG003","value":"-10.17","spread":"0.56"}]}]}]},{"type":"SECONDARY","title":"Change in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7","description":"The difference between the last available troughs represents the additional reduction in DBP in this study","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.54","spread":"0.33"},{"groupId":"OG001","value":"-5.52","spread":"0.55"},{"groupId":"OG002","value":"-5.51","spread":"1.59"},{"groupId":"OG003","value":"-5.74","spread":"0.58"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough Seated Systolic Blood Pressure","description":"Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.5.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.79","spread":"0.52"},{"groupId":"OG001","value":"-15.91","spread":"0.86"},{"groupId":"OG002","value":"-12.6","spread":"2.5"},{"groupId":"OG003","value":"-14.04","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Change in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7","description":"The difference between the last available troughs represents the additional reduction in SBP in this study","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.14","spread":"0.5"},{"groupId":"OG001","value":"-5.62","spread":"0.83"},{"groupId":"OG002","value":"-3.6","spread":"2.41"},{"groupId":"OG003","value":"-7.17","spread":"0.88"}]}]}]},{"type":"SECONDARY","title":"Trough Seated DBP Response","description":"The number of patients who reach the target DBP of \\<90mmHg or had a reduction in DBP \\>= 10mmHg","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"504","spread":null},{"groupId":"OG001","value":"171","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Seated SBP Response","description":"The number of patients who reach the target SBP of \\<140mmHg or had a reduction in SBP \\>= 15 mmHg","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"490","spread":null},{"groupId":"OG001","value":"179","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"128","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Blood Pressure (BP) Normality Classes","description":"The number of patients who reach predefined BP categories","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Additional Antihypertensive","description":"Time from first intake of medication to first intake of an antihypertensive other than the study drug","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8","spread":"38.4"}]}]}]},{"type":"SECONDARY","title":"Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control","description":"The number of patients with DBP control (DBP\\<90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"206","spread":null},{"groupId":"OG002","value":"218","spread":null}]}]}]},{"type":"SECONDARY","title":"Additional Reduction in DBP by Use of Additional Antihypertensive Therapy","description":"Difference in trough DBP from last visit before add-on therapy and last visit during 1235.7","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.73","spread":"7.65"}]}]}]},{"type":"SECONDARY","title":"Additional Reduction in SBP by Use of Additional Antihypertensive Therapy","description":"Difference in trough SBP from last visit before add-on therapy and last visit during 1235.7","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.53","spread":"11.21"}]}]}]},{"type":"SECONDARY","title":"Trough DBP Control Pre- and Post- Uptitration","description":"The number of patients with DBP control (DBP\\<90 mmHg). Last trough DBP measurement before uptitration to Telmisartan 80mg compared to first trough DBP taken after uptitration","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"190","spread":null},{"groupId":"OG002","value":"207","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"171","spread":null},{"groupId":"OG002","value":"171","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"361","spread":null},{"groupId":"OG002","value":"378","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":976},"commonTop":["Oedema peripheral","Back pain"]}}}